26Aug 2023
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents

A Phase 1/2 clinical trial assessed the "Sputnik V" vaccine in adolescents aged 12-17, using reduced doses. Both doses were well-tolerated, with no severe adverse events. The 1/5 dose induced stronger immune responses, including cross-neutralization of Delta and Omicron variants. The study emphasizes safety and efficacy in young individuals.

  • #family health

Like

Save

Share